Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine.

IF 5.5 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-02-27 DOI:10.1080/14760584.2024.2320861

Viravarn Luvira, Punnee Pitisuttithum

{"title":"Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine.","authors":"Viravarn Luvira, Punnee Pitisuttithum","doi":"10.1080/14760584.2024.2320861","DOIUrl":null,"url":null,"abstract":"Introduction: Inactivated vaccines were delivered to low- and middle-income countries during the early pandemics of COVID-19. Currently, more than 10 inactivated COVID-19 vaccines have been developed. Most inactivated vaccines contain an inactivated whole-cell index SARS-CoV-2 strain that is adjuvant. Whole virions inactivated with aluminum hydroxide vaccines were among the most commonly used. However, with the emerging of COVID-19 variants and waning of the immunity of two doses of after 3 months, WHO and many local governments have recommended the booster-dose program especially with heterologous platform vaccine.Area covered: This review was conducted through a literature search of the MEDLINE database to identify articles published from 2020 to 2023 covered the inactivated COVID-19 vaccines primary series with homologous and heterologous booster focusing on safety, immunogenicity, efficacy, and effectiveness.Expert opinion: The inactivated vaccines, especially whole virion inactivated in aluminum hydroxide appeared to be safe and had good priming effects. Immune responses generated after one dose of heterologous boost were high and able to preventing severity of disease and symptomatic infection. A new approach to inactivated vaccine has been developed using inactivating recombinant vector virus-NDV-HXP-S vaccine.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2024.2320861","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Inactivated vaccines were delivered to low- and middle-income countries during the early pandemics of COVID-19. Currently, more than 10 inactivated COVID-19 vaccines have been developed. Most inactivated vaccines contain an inactivated whole-cell index SARS-CoV-2 strain that is adjuvant. Whole virions inactivated with aluminum hydroxide vaccines were among the most commonly used. However, with the emerging of COVID-19 variants and waning of the immunity of two doses of after 3 months, WHO and many local governments have recommended the booster-dose program especially with heterologous platform vaccine.

Area covered: This review was conducted through a literature search of the MEDLINE database to identify articles published from 2020 to 2023 covered the inactivated COVID-19 vaccines primary series with homologous and heterologous booster focusing on safety, immunogenicity, efficacy, and effectiveness.

Expert opinion: The inactivated vaccines, especially whole virion inactivated in aluminum hydroxide appeared to be safe and had good priming effects. Immune responses generated after one dose of heterologous boost were high and able to preventing severity of disease and symptomatic infection. A new approach to inactivated vaccine has been developed using inactivating recombinant vector virus-NDV-HXP-S vaccine.

查看原文本刊更多论文

同源或异源疫苗强化剂对最初两剂 COVID-19 灭活疫苗的影响。

导言：在 COVID-19 的早期大流行期间，灭活疫苗曾被提供给低收入和中等收入国家。目前，已开发出 10 多种 COVID-19 灭活疫苗。大多数灭活疫苗都含有带有佐剂的灭活全细胞指数 SARS-CoV-2 株。氢氧化铝全病毒灭活疫苗是最常用的疫苗之一。然而，随着 COVID-19 变异株的出现以及三个月后两剂免疫力的减弱，世卫组织和许多地方政府都建议实施加强剂量计划，尤其是使用异源平台疫苗：本综述通过MEDLINE数据库进行文献检索，找出2020年至2023年发表的涉及COVID-19灭活疫苗初级系列与同源和异源加强剂的文章，重点关注安全性、免疫原性、效力和有效性：灭活疫苗，尤其是氢氧化铝灭活的全病毒似乎是安全的，并具有良好的启动效应。接种一剂异源增强剂后产生的免疫反应较高，能够预防疾病的严重程度和无症状感染。使用重组载体病毒-NDV-HXP-S 灭活疫苗开发了新的灭活疫苗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.